中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性乙型肝炎防治指南

引用本文:
Citation:

慢性乙型肝炎防治指南

详细信息
  • 中图分类号: R512.62

  • [1]Lok ASF, McMahon BJ.AASLD practice guidelines:chronic hepatitisB.Hepatology, 2001, 34∶1225-1241.
    [2]Seeger C, Mason W.Hepatitis B virus biology.Microbiol Mol Biol Rev, 2000, 64∶51-68.
    [3]Scaglioni PP, Melegari M, Wands JR.Biologic properities of hepatitis Bviral genomes with mutations in the precore promoter and precore openreading frame.Virology, 1997, 233∶374-381.
    [4]Lai CL, Dienstag J, Schiff E, et al.Prevalence and clinical correlates ofYMDD variants during lamivudine therapy for patients with chronic hep-atitis B.Clin Infect Dis, 2003, 36∶687-696.
    [5]Hu KQ.Occult hepatitis B virus infection and its clinical implications.JViral Hepat, 2002, 9∶243-257.
    [6]Janssen HL, van Zonneveld M, Senturk H, et al.Pegylated interferonalfa-2b alone or in combination with lamivudine for HBeAg-positivechronic hepatitis B:a randomised trial.Lancet, 2005, 365∶123-129.
    [7] World Health Organization.Hepatitis B.World Health Organization FactSheet 204 dex. (Revised October 2000) .WHO Web site.http://www.who.int/mediacentre/factsheets/fs204/en/in html.
    [8]梁晓峰, 陈园生, 王晓军, 等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志, 2005, 26∶655-658.
    [9]范金水, 庄辉, 李远贵, 等.我国8城市HBsAg阳性和阴性乙型肝炎患者的病毒血清型和基因型分析.中华微生物学和免疫学杂志, 1998, 18∶88-91.
    [10] EASL International Consensus Conference on Hepatitis B.J Hepatol, 2003, 39 (Suppl) ∶S3-S25.
    [11]Lok ASF, Heathcote EJ, Hoofnagle JH.Management of hepatitis B:2000 summary of a workshop.Gastroenterology, 2001, 120∶1828-1853.
    [12]McMahon BJ, Alward WL, Hall DB, et al.Acute hepatitis B virus in-fection:relation of age to the clinical expression of disease and subsequentdevelopment of the carrier state.J Infect Dis, 1985, 151∶599-603.
    [13]Bortolotti F, Cadrobbi P, Crivellaro C, et al.Long-term outcome ofchronic type B hepatitis in patients who acquire hepatitis B virus infectionin childhood.Gastroenterology, 1990, 99∶805-810.
    [14]McMahon BJ, Holck P, Bulkow L, et al.Serologic and clinical out-comes of 1536 Alaska Natives chronically infected with hepatitis B virus.Ann Intern Med, 2001, 135∶759-768.
    [15]Liaw YF, Tai DI, Chu CW, et al.The development of cirrhosis in pa-tients with chronic type B hepatitis:a prospective study.Hepatology, 1988, 8∶493-496.
    [16] Hsu YS, Chien RN, Yeh CT, et al.Long-term outcome after sponta-neous HBeAg serocoversion in patints with chronic hepatitis B.Hepatolo-gy, 2002, 35∶1522-1527.
    [17]Liaw YF, Tai DI, Chu CW, et al.Natural course after the developmentof cirrhosis in patients with chronic type B hepatitis:a prospective study.Liver, 1989, 9∶235-241.
    [18]Di Marco V, Lo Lacono O, Camma C, et al.The long-term course ofchronic hepatitis B.Hepatology, 1999, 30∶257-264.
    [19]Brunetto MR, Oliveri F, Rocca G, et al.Natural course and responseto interferon of chronic hepatitis B accompanied by antibody to hepatitis Be antigen.Hepatology, 1989, 10∶198-202.
    [20]Fattovich G, Brollo L, Alberti A, et al.Long-term follow-up of anti-HBe-positive chronic active hepatitis B.Hepatology, 1988, 8∶1651-1654.
    [21]Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patients withchronic hepatitis B and advanced liver disease.N Engl J Med, 2004, 351∶1521-1531.
    [22]Yang HI, Lu SN, Liaw YF, et al.Hepatitis B e antigen and the risk ofhepatocellular carcinoma.N Engl J Med, 2002, 347∶168-174.
    [23]Lavanchy D.Hepatitis B virus epidemiology, disease burden, treat-ment, and current and emerging prevention and control measures.J ViralHepat, 2004, 11∶97-107.
    [24]Tai DI, Chen CH, Chang TT, et al.Eight-year nationwide survivalanalysis in relatives of patients with hepatocellular carcinoma:role of viralinfection.J Gastroenterol Hepatol, 2002, 17∶682-689.
    [25] 中国疾病预防控制中心.乙型肝炎疫苗儿童计划免疫技术管理规程 (试行) .2002.
    [26]夏国良, 龚健, 王继杰, 等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价.中华流行病学杂志, 2003, 24∶362-365.
    [27] Hepatitis B.http://www.who.int/csr/disease/hepatitis/whocdscsrly-o2002 2./ou/.
    [28] 邢玉兰, 龚晓红, 周绍莲, 等.阻断围产期母婴传播最佳免疫方案的研究.中华实验和临床病毒学杂志, 1990, 4∶485-488.
    [29] CDC.Hepatitis B.http://www.cdc.gov/ncidod/diseases/hepatitis/b/education/hbv and you chi.pdf WHO.Hepatitis B and breastfeed-ing.http://www.who.int/child-adolescent-health/New Publica-tions/NUTRITION/updt-22.htm (online on Oct 23, 2005)
    [30]John T J, Cooksley G.Hepatitis B vaccine boosters:Is there a clinicalneed in high endemicity populations?J Gastroenterol Hepatol, 2005, 20∶5-10.
    [31]Updated U.S.public health service guidelines for the management ofoccupational exposures to HBV, HCV and HIV and recommendations forpostexposure prophylaxis.MMWR Recomm Rep, 2001, 50 (RR-11) ∶1-52.
    [32] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案.中华肝脏病杂志, 2000, 8∶342-329.
    [33]Roque-Afonse AM, Ferey MP, Mackiwicz V, et al.Monitoring the e-mergence of hepatitis B virus polymerase gene variants during lamivudinetherapy in human immunodeficiency virus coinfected patients, perfor-mance of CLIP sequencing and line probe assay.Antivir Ther, 2003, 8∶627-634.
    [34]Whalley SA, Brown D, Teo CG, et al.Monitoring the emergence ofhepatitis B virus polymerase gene variants during lamivudine therapy usingLightCycler.J Clin Microbiol, 2001, 39∶1456-1459.
    [35]Ishak KG.Pathologic features of chronic hepatitis.A review and up-date.Am J clin Pathol, 2000, 113∶40-45.
    [36]Knodell RG, Ishak KG, Black WC, et al.Formulation and applicationof a numerical scoring system for assessing histological activity in asymp-tomatic chronic active hepatitis.Hepatology, 1998, 11∶431-435.
    [37] Scheuer PJ.Standish RA.Dhillon AP.Scoring of chronic hepatitis.Clin Liver Dis, 2002, 2002, 6∶335-347.
    [38]Chevallier M, Guerret S, Chossegros P, et al.A histological semiquan-titative scoring system for evaluation of hepatic fibrosis in needle liverbiopsy specimens:comparison with morphometric studies.Hepatology, 1994, 20∶349-355.
    [39]Wong DK, Cheung AM, O’Rourke K, et al.Effect of alpha-interfer-on treatment in patients with hepatitis B e antigen-positive chronic hep-atitis B:a meta-analysis.Ann Intern Med, 1993, 119∶312-323.
    [40]Lampertico P, Del Ninno E, Manzin A, et al.A randomized, con-trolled trial of a 24-month course of interferon alpha 2b in patients withchronic hepatitis B who had hepatitis B virus DNA without hepatitis eantigen in serum.Hepatology, 1997, 26∶1621-1625.
    [41]Fattovich G, Farci P, Rugge M, et al.A randomized controlled trial oflymphoblastoid interferon-alpha in patients with chronic hepatitis B lack-ing HBeAg.Hepatology, 1992, 15∶584-589.
    [42]Manesis EK, Hadziyannis SJ.Interferon alpha treatment and retreatmentof hepatitis B e antigen-negative chronic hepatitis B.Gastroenterology, 2001, 121∶101-109.
    [43]马为民, 陆坚, 蒋小玲, 等.干扰素α-1b治疗慢性乙型肝炎的疗效及其预测因素的分析.中华传染病杂志, 2001, 19∶148-151.
    [44]毛乾国, 骆抗先, 傅群芳, 等.干扰素α对慢性乙型肝炎e抗原阴性患者的疗效及影响因素.中华肝脏病杂志, 2004, 12∶582-584.
    [45] Hoofnagle JH, DiBisceglie AM, Waggoner JG, et al.Interferon alfa forpatients with clinically apparent cirrhosis due to chronic hepatitis B.Gas-troenterology, 1993, 104∶1116-1121.
    [46]Harris JM, Martin NE, Modi M.Pegylation:a novel process for modify-ing pharmacokinetics.Clin Pharmacokinet, 2001, 40∶539-551.
    [47]Lau GK, Piratvisuth T, Luo KX, et al.Peginterferon Alfa-2a, lamivu-dine, and the combination for HBeAg-positive chronic hepatitis B.NEngl J Med, 2005, 352∶2682-2695.
    [48]Marcellin P, Lau GKK, Bonino F, et al.Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med, 2004, 351∶1206-1217.
    [49]Cooksley WGF, Piratvisuth T, Lee SD, et al.Peginterferon alpha 2a (40 kDa) :an advance in the treatment of hepatitis B e antigen-positivechronic hepatitis B.J Viral Hepat, 2003, 10∶298-305.
    [50]Carreno V, Marcellin P, Hadziyannis S, et al.Retreatment of chronichepatitis B e antigen-positive patients with recombinant interferon alfa-2a.The European Concerted A ction on Viral Hepatitis (EUROHEP) .Hepatology, 1999, 30∶277-282.
    [51]Janssen HL, Gerken G, Carreno V, et al.Interferon alfa for chronichepatitis B infection:increased efficacy of prolonged treatment.The Euro-pean Concerted Action on Viral Hepatitis (EUROHEP) .Hepatology, 1999, 30∶238-243.
    [52] Sokal R.Drug treatment of paediatric chronic hepatitis B.PeadiatrDrugs, 2002, 4∶361-369.
    [53]Hoofnagle JH, Dibisceglie AM.The treatment of chronic viral hepatitis.N Engl J Med, 1997, 5336∶347-356.
    [54]Brook MG, Karayiannis P, Thomas HC.Which patients with chronichepatitis B virus infection will respond to alpha-interferon therapy?Hepatology, 1989, 10∶761-763.
    [55]Lok AS, Lai CL, Leung N, et al.Long-term safety of lamivudinetreatment in patients with chronic hepatitis B.Gastroenterology, 2003, 125∶1714-1722.
    [56]Lai CL, Chien RN, Leung NW, et al.A one-year trial of lamivdinefor chronic hepatitis B.Asia Hepatitis Lamivudine Study Group.N Engl JMed, 1998, 339∶61-68.
    [57]Liaw YF, Leung NW, Chang TT, et al.Effects of extended lamivudinetherapy in Asian patients with chronic hepatitis B.Asia Hepatitis Lamivu-dine Study Group.Gastroenterology, 2000, 119∶172-180.
    [58]Dienstag JL, Schiff ER, Wright TL, et al.Lamivudine as initial treat-ment for chronic hepatitis B in the United States.N Engl J Med, 1999, 341∶1256-1263.
    [59]Chien RN, Liaw YF, Atkins M.Pretherapy alanine transaminase levelas a determinant for hepatitis B e antigen seroconversion during lamivu-dine therapy in patients with chronic hepatitis B.Asian Hepatitis Lamivu-dine Trial Group.Hepatology, 1999, 30∶770-774.
    [60]Dienstag JL, Goldin RD, Heathcote EJ, et al.Histological outcomeduring long-term lamivudine therapy.Gastroenterology, 2003, 124∶105-117.
    [61] Villeneuve JP, Condreay LD, Willems B, et al.Lamivudine treatmentfor decompensated cirrhosis resulting from chronic hepatitis B.Hepatolo-gy, 2000, 31∶207-210.
    [62]Perrillo RP, Wright T, Rakela J, et al.A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after livertransplantation for chronic hepatitis B.Hepatology, 2001, 33∶424-432.
    [63]Hann HW, Fontana RJ, Wright T, et al.A United States compassionateuse study of lamivudine treatment in nontransplantation candidates withdecompensated hepatitis B virus-related cirrhosis.Liver Transpl, 2003, 9∶49-56.
    [64]Jonas MM, Mizerski J, Badia IB, et al.Clinical trial of lamivudine inchildren with chronic hepatitis B.N Engl J Med, 2002, 346∶1706-1713.
    [65] Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al.Efficacyof lamivudine in the treatment of children with chronic hepatitis B.Hepa-tol Res, 2005, 31∶217-222.
    [66]姚光弼, 王宝恩, 崔振宇, 等.拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志, 2003, 42∶382-387.
    [67]姚光弼, 崔振宇, 姚集鲁, 等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验.中华肝脏病杂志, 2003, 11∶103-108.
    [68]Liaw YF, Chien RN, Yeh CT, et al.Acute exacerbation and hepatitisB virus clearance after emergence of YMDD motif mutation during lamivu-dine therapy.Hepatology, 1999, 30∶567-572.
    [69]Liu CJ, Huang WL, Chen PJ, et al.End-of-treatment virologic re-sponse does not predict relapse after lamivudine treatment for chronic hep-atitis B.World J Gastroenterol, 2004, 10∶3574-3578.
    [70]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treat-ment of hepatitis B e antigen-positive chronic hepatitis B.N Engl JMed, 2003, 348∶808-816.
    [71] Macellin P, Chang TT, Lim S, et al.Long term efficacy and safety ofadefovir dipivoxil 10 mg in HBeAg+chronic hepatitis B patients:increas-ing serologic, virologic and biochemical response over time.Hepatology, 2004, 40 (4, suppl) ∶655A.
    [72]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.Adefovir dip-ivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitisB.N Engl J Med, 2003, 348∶800-807.
    [73]Locarnini S, Shaw T, Sozzi T, et al.HBV mutants associated with clin-ical resistance to adefovir dipivoxil display only small decreases in antivi-ral sensitivity in vitro.Hepatology, 2004, 40 (4 suppl) ∶244A.
    [74]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.Long-termtherapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.N Engl J Med, 2005, 352∶2673-2681.
    [75]Peters MG, Hann HW, Martin P, et al.Adefovir dipivoxil alone or incombination with lamivudine in patients with lamivudine-resistant chron-ic hepatitis B.Gastroenterology, 2004, 126∶91-101.
    [76]Perrillo R, Hann HW, Mutimer D, et al.Adefovir dipivoxil added toongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis Bvirus.Gastroenterology, 2004, 126∶81-90.
    [77]Izzedine H, Hulot JS, Launay-Vacher V, et al.Renal safety of ade-fovir dipivoxil in patients with chronic hepatitis B:two double-blind, randomized, placebo-controlled studies.Kidney Int, 2004, 66∶1153-1158.
    [78]Lai CL, Rosmawati M, Lao J, et al.Entecavir is superior to lamivudinein reducing hepatitis B virus DNA in patients with chronic hepatitis B in-fection.Gastroenterology, 2002, 123∶1831-1838.
    [79]姚光弼, 张定凤, 王宝恩, 等.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究.中华肝脏病杂志, 2005, 13∶484-487.
    [80]姚光弼, 任红, 王宝恩, 等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究.肝脏, 2005, 10∶2-4.
    [81] Colonno RJ, Rose R, Levine SM, et al.Emergence of entecavir resis-tant hepatitis B virus after one year of therapy in phaseⅡ&Ⅲstudies isonly observed in lamivudine refractory patients.Hepatology, 2004, 40 (4, suppl 1) ∶661A.
    [82]陆伦根, 曾民德, 茅益民, 等.氧化苦参碱胶囊治疗慢性乙型病毒性肝炎的随机双盲、安慰剂对照多中心临床研究.肝脏, 2002, 7∶218-221.
    [83]于岩岩, 王勤环, 朱理珉, 等.苦参素治疗慢性乙型肝炎的临床研究.中华肝脏病杂志, 2002, 10∶280-282.
    [84]于岩岩, 斯崇文, 曾争, 等.苦参素制剂治疗慢性乙型肝炎的临床实验, 中华内科杂志, 2001, 40∶843-846.
    [85] Liaw YF, Leung N, Guan R, et al.Asian-Pacific consensus statementon the management of chronic hepatitis B:a 2005 update.Liver Interna-tional, 2005, 25∶472-489.
  • 加载中
计量
  • 文章访问数:  1901
  • HTML全文浏览量:  3
  • PDF下载量:  765
  • 被引次数: 0
出版历程
  • 出版日期:  2006-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回